Erythropoietin neuroprotection with traumatic brain injury

Pathophysiology

Volumn 20, Issue 1, 2013, Pages 31-38

  Ponce, Lucido L ^a   Navarro, Jovany Cruz ^a   Ahmed, Osama ^b   Robertson, Claudia S ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Erythropoietin; Neuroprotection; Traumatic brain injury

Indexed keywords

CD131 ANTIGEN; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEPTIDE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PYROGLUTAMATE HELIX B SURFACE PEPTIDE; UNCLASSIFIED DRUG;

ANEMIA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN EDEMA; CIRCULATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG FATALITY; DRUG TARGETING; ERYTHROPOIESIS; EXCITOTOXICITY; HALF LIFE TIME; HUMAN; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; RECEPTOR BINDING; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; THROMBOEMBOLISM; TRAUMATIC BRAIN INJURY;

EID: 84878207354     PISSN: 09284680     EISSN: 1873149X     Source Type: Journal    
DOI: 10.1016/j.pathophys.2012.02.005     Document Type: Article

References (86)

1. Langlois J.A., Rutland-Brown W., Wald M.M. The epidemiology and impact of traumatic brain injury: a brief overview. J. Head Trauma Rehabil. 2006, 21:375-378.
2. Tagliaferri F., Compagnone C., Korsic M., Servadei F., Draus J. A systematic review of brain injury epidemiology in Europe. Acta Neurochir. (Wien) 2006, 148:255-268.
3. McAllister T.W., Sparling M.B., Flashman L.A., Guerin S.J., Mamourian A.C., Saykin A.J. Differential working memory load effects after mild traumatic brain injury. Neuroimage 2001, 14:1004-1012.
4. Alves W., Macciocchi S.N., Barth J.T. Postconcussive symptoms after uncomplicated mild head injury. J. Head Trauma Rehabil. 1993, 8:48-59.
5. Englander J., Hall K., Stimpson T., Chaffin S. Mild traumatic brain injury in an insured population: subjective complaints and return to employment. Brain Inj. 1992, 6:161-166.
6. Lin F.K., Suggs S., Lin C.H., Browne J.K., Smalling R., Egrie J.C., Chen K.K., Fox G.M., Martin F., Stabinsky Z., Badrawi S.M., Lai P.-H., Goldwasser E. Cloning and expression of the human erythropoietin gene. Proc. Natl. Acad. Sci. U.S.A. 1985, 82:7580-7584.
7. Carnot M., Deflandre C. Comptes Rendus Hebdomadaires des Seances de l'Acad des Sci. 1906, 143:384-386.
8. Erslev A.J. Humoral regulation of red cell production. Blood 1953, 8:349-357.
9. Jacobson L.O., Goldwasser E., Fried W., Plazak L. Role of the kidney in erythropoiesis. Nature 1957, 179:633-634.
10. Erslev A.J. In vitro production of erythropoietin by kidneys perfused with a serum-free solution. Blood 1974, 44:77-80.
11. Bondurant M.C., Koury M. Anemia induces accumulation of erythropoietin mRNA in the kidney and liver. Mol. Cell. Biol. 1986, 6:2731-2733.
12. Beru N., McDonald J., Lacombe C., Goldwasser E. Expression of the erythropoietin gene. Mol. Cell. Biol. 1986, 6:2571-2575.
13. Schuster S.J., Wilson J., Erslev A.J., Caro J. Physiologic regulation and tissue localization of renal erythropoietin mRNA. Blood 1987, 70:316-318.
14. Jones N.M., Bergeron M. Hypoxic preconditioning induces changes in HIF-1 target genes in neonatal rat brain. J. Cereb. Blood Flow Metab. 2001, 21:1105-1114.
15. Jelkmann W. Molecular biology of erythropoietin. Intern. Med. 2004, 43:649-659.
16. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol. Rev. 1992, 72:449-489.
17. Sytkowski A.J. Erythropoietin: Blood, Brain and Beyond 2004, Wiley, Weinheim.
18. Erslev A.J., Caro J., Kansu E., Silver R. Renal and extrarenal erythropoietin production in anemic rats. Br. J. Haematol. 1980, 45:65-72.
19. Caro J., Brown S., Miller O., Murray T., Erslev A.J. Erythropoietin levels in uremic nephric and anephric patients. J. Lab. Clin. Med. 1979, 93:449-458.
20. Marti H.H., Wenger R.H., Rivas L.A., Straumann U., Digicaylioglu M., Henn V., Tonekawa T., Bauer C., Gassmann M. Erythropoietin gene expression in human, monkey and murine brain. Eur. J. Neurosci. 1996, 8:666-676.
21. Chikuma M., Masuda S., Kobayashi T., Nagao M., Sasaki R. Tissue specific regulation of erythropoietin production in the murine kidney, brain, and uterus. Am. J. Physiol. Endocrinol. Metab. 2000, 279:E1242-E1248.
22. Warnecke C., Zaborowska Z., Kurreck J. Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB J. 2004, 18:1462-1464.
23. Kawakami M., Sekiguchi M., Sato K., Kozaki S., Takahashi M. Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J. Biol. Chem. 2001, 276:39469-39475.
24. Sola A., Rogido M., Lee B.H., Genetta T., Wen T.C. Erythropoietin after focal cerebral ischemia activates the Janus kinase-signal transducer and activator of transcription signaling pathway and improves brain injury in postnatal day 7 rats. Pediatr. Res. 2005, 57:481-487.
25. Sola A., Wen T.C., Hamrick S.E., Ferriero D.M. Potential for protection and repair following injury to the developing brain: a role for erythropoietin?. Pediatr. Res. 2005, 57:110R-117R.
26. Koshimura K., Murakami Y., Sohmiya M., Tanaka J., Kato Y. Effects of erythropoietin on neuronal activity. J. Neurochem. 1999, 72:2565-2572.
27. Kilic E., Kilic U., Soliz J., Bassetti C.L., Gassmann M., Hermann D.M. Brain-derived erythropoietin protects from focal cerebral ischemia by dual activation of ERK-1/-2 and Akt pathways. FASEB J. 2005, 19:2026-2028.
28. Kilic U., Kilic E., Soliz J., Bassetti C.I., Gassmann M., Hermann D.M. Erythropoietin protects from axotomy-induced degeneration of retinal ganglion cells by activating ERK-1/-2. FASEB J. 2005, 19:249-251.
29. Chong Z.Z., Kang J.Q., Maiese K. Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways. Br. J. Pharmacol. 2003, 138:1107-1118.
30. Chong Z.Z., Lin S.H., Kang J.Q., Maiese K. Erythropoietin prevents early and late neuronal demise through modulation of Akt1 and induction of caspase 1, 3, and 8. J. Neurosci. Res. 2003, 71:659-669.
31. Byts N., Samoylenko A., Fasshauer T., Ivanisevic M., Hennighausen L., Ehrenreich H., Sirén A.L. Essential role for Stat5 in the neurotrophic but not in the neuroprotective effect of erythropoietin. Cell Death Differ. 2008, 15:783-792.
32. Wu Y., Shang Y., Sun S., Liang H., Liu R. Erythropoietin prevents PC12 cells from 1-methyl-4-phenylpyridinium ion-induced apoptosis via the Akt/GSK-3beta/caspase-3 mediated signaling pathway. Apoptosis 2007, 12:1365-1375.
33. Zhang F., Signore A.P., Zhou Z., Wang S., Cao G., Chen J. Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms. J. Neurosci. Res. 2006, 83:1241-1251.
34. Zhang F., Wang S., Cao G., Gao Y., Chen J. Signal transducers and activators of transcription 5 contributes to erythropoietin-mediated neuroprotection against hippocampal neuronal death after transient global cerebral ischemia. Neurobiol. Dis. 2007, 25:45-53.
35. Culmsee C., Mattson M.P. p53 in neuronal apoptosis. Biochem. Biophys. Res. Commun. 2005, 331:761-777.
36. Datta S.R., Brunet A., Greenberg M.E. Cellular survival: a play in three Akts. Genes Dev. 1999, 13:2905-2927.
37. Sirén A.L., Fratelli M., Brines M., Goemans C., Casagrande S., Lewczuk P., Keenan S., Gleiter C., Pasquali C., Capobianco A., Mennini T., Heumann R., Cerami A., Ehrenreich H., Ghezzi P. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:4044-4049.
38. Wei L., Han B.H., Li Y., Keogh C.L., Holtzman D.M., Yu S.P. Cell death mechanism and protective effect of erythropoietin after focal ischemia in the whisker-barrel cortex of neonatal rats. J. Pharmacol. Exp. Ther. 2006, 317:109-116.
39. Chong Z.Z., Maiese K. Erythropoietin involves thephosphatidylinositol 3-kinase pathway, 14-3-3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity. Br. J. Pharmacol. 2007, 150:839-850.
40. Chong Z.Z., Li F., Maiese K. Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity. Curr. Neurovasc. Res. 2005, 2:387-399.
41. Corwin H.L., Gettinger A., Fabian T.C., May A., Pearl R.G., Heard S., An R., Bowers P.J., Burton P., Klausner M.A., Corwin M.J. Efficacy and safety of epoetin alfa in critically ill patients. N. Engl. J. Med. 2007, 357:965-976.
42. Zarychanski R., Turgeon A.F., McIntyre L., Fergusson D.A. Erythropoietin-receptor-agonists in critically ill patients: a meta-analysis of randomized clinical trials. CMAJ 2007, 77:725-734.
43. Napolitano L.M., Fabian T.C., Kelly K.M., Bailey J.A., Block E.F., Langholff W., Enny C., Corwin H.L. Improved survival of critically ill trauma patients treated with recombinant human erythropoietin. J. Trauma 2008, 65:285-297.
44. Talving P., Lustenberger T., Kobayashi L., Inaba K., Barmparas G., Schnuriger B., Lam L., Chan L.S., Demetriades D. Erythropoiesis stimulating agent administration improves survival after severe traumatic brain injury: a matched case control study. Ann. Surg. 2010, 251:1-4.
45. Solaroglu I., Solaroglu A., Kaptanoglu E., Dede S., Haberal A., Beskonakli E., Kilinc K. Erythropoietin prevents ischemia-reperfusion from inducing oxidative damage in fetal rat brain. Childs Nerv. Syst. 2003, 19:19-22.
46. Wu Y., Shang Y., Sun S., Liu R. Antioxidant effect of erythropoietin on 1-methyl-4-phenylpyridinium-induced neurotoxicity in PC12 cells. Eur. J. Pharmacol. 2007, 564:47-56.
47. Chattopadhyay A., Choudhury T.D., Bandyopadhyay D., Datta A.G. Protective effect of erythropoietin on the oxidative damage of erythrocyte membrane by hydroxyl radical. Biochem. Pharmacol. 2000, 59:419-425.
48. Kumral A., Gonenc S., Acikgoz O., Sonmez A., Genc K., Yilmaz O., Gokmen N., Duman N., Ozkan H. Erythropoietin increases glutathione peroxidase enzyme activity and decreases lipid peroxidation levels in hypoxic-ischemic brain injury in neonatal rats. Biol. Neonate 2005, 87:15-18.
49. Kawakami M., Iwasaki S., Sato K., Takahashi M. Erythropoietin inhibits calcium-induced neurotransmitter release from clonal neuronal cells. Biochem. Biophys. Res. Commun. 2000, 279:293-297.
50. Wang L., Zhang Z., Wang Y., Zhang R., Chopp M. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004, 35:1732-1737.
51. Ribatti D., Vacca A., Roccaro A.M., Crivellato E., Presta M. Erythropoietin as an angiogenic factor. Eur. J. Clin. Invest. 2003, 33:891-896.
52. Marti H.H., Bernaudin M., Petit E., Bauer C. Neuroprotection and angiogenesis: dual role of erythropoietin in brain ischemia. News Physiol. Sci. 2000, 15:225-229.
53. Jaquet K., Krause K., Tawakol-Khodai M., Geidel S., Kuck K.H. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc. Res. 2002, 64:326-333.
54. Cherian L., Goodman J.C., Robertson C. Neuroprotection with erythropoietin administration following controlled cortical impact injury in rats. J. Pharmacol. Exp. Ther. 2007, 322:789-794.
55. Xiong Y., Mahmood A., Qu C., Kazmi H., Zhang Z.G., Noguchi C.T., Schallert T., Chopp M. Erythropoietin improves histological and functional outcomes after traumatic brain injury in mice in the absence of the neural erythropoietin receptor. J. Neurotrauma 2010, 27:205-215.
56. Xiong Y., Mahmood A., Lu D., Qu C., Kazmi H., Goussev A., Zhang Z.G., Noguchi C.T., Schallert T., Chopp M. Histological and functional outcomes after traumatic brain injury in mice null for the erythropoietin receptor in the central nervous system. Brain Res. 2008, 1230:247-257.
57. Xiong Y., Mahmood A., Meng Y., Zhang Y., Qu C., Schallert T., Chopp M. Delayed administration of erythropoietin reducing hippocampal cell loss, enhancing angiogenesis and neurogenesis, and improving functional outcome following traumatic brain injury in rats: comparison of treatment with single and triple dose. J. Neurosurg. 2010, 113:598-608.
58. Meng Y., Xiong Y., Mahmood A., Zhang Y., Qu C., Chopp M. Dose-dependent neurorestorative effects of delayed treatment of traumatic brain injury with recombinant human erythropoietin in rats. J. Neurosurg. 2011, [Epub ahead of print, April 15]. 10.3171/2011.3.JNS101721.
59. Wang L., Zhang Z.G., Zhang R.L., Gregg S.R., Hozeska-Solgot A., LeTourneau Y., Wang Y., Chopp M. Matrix metalloproteinase 2 (MMP2) and MMP9 secreted by erythropoietin-activated endothelial cells promote neural progenitor cell migration. J. Neurosci. 2006, 26:5996-6003.
60. Brines M.L., Ghezzi P., Keenan S., Agnello D., de Lanerolle N.C., Cerami C., Itri L.M., Cerami A. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:10526-10531.
61. Juul S.E., McPherson R.J., Farrell F.X., Jolliffe L., Ness D.J., Gleason C.A. Erythropoietin concentrations in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietin. Biol. Neonate 2004, 85:138-144.
62. Banks W.A., Jumbe N.L., Farrell C.L., Niehoff M.L., Heatherington A.C. Passage of erythropoietic agents across the blood-brain barrier: a comparison of human and murine erythropoietin and the analog darbepoetin alfa. Eur. J. Pharmacol. 2004, 505:93-101.
63. Xiong Y., Mahmood A., Lu D., Qu C., Goussev A., Schallert T., Chopp M. Role of gender in outcome after traumatic brain injury and therapeutic effect of erythropoietin in mice. Brain Res. 2007, 1175:301-312.
64. Lu D., Mahmood A., Goussev A., Schallert T., Chopp M. Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury. J. Neurotrauma 2005, 22:1011-1017.
65. Jin W., Kong J., Lu T., Wang H., Ni H., Wu J., Jiang J., Liang W. Erythropoietin prevents secondary brain injury induced by cortical lesion in mice: possible involvement of Nrf2 signaling pathway. Ann. Clin. Lab. Sci. 2011, 41:25-32.
66. Zhu L., Wang H.D., Yu X.G., Jin W., Qiao L., Lu T.J., Hu Z.L., Zhou J. Erythropoietin prevents zinc accumulation and neuronal death after traumatic brain injury in rat hippocampus: in vitro and in vivo studies. Brain Res. 2009, 1289:96-105.
67. Adembri C., Bechi A., Meli E., Gramigni E., Venturi L., Moroni F., De Gaudio A.R., Pellegrini-Giampietro D.E. Erythropoietin attenuates post-traumatic injury in organotypic hippocampal slices. J. Neurotrauma 2004, 21:1103-1112.
68. Pinzon A., Marcillo A., Pabon D., Bramlett H.M., Bunge M.B., Dietrich W.D. A re-assessment of erythropoietin as a neuroprotective agent following rat spinal cord compression or contusion injury. Exp. Neurol. 2008, 213:120-136.
69. Mann C., Lee J.H., Liu J., Stammers A.M., Sohn H.M., Tetzlaff W., Kwon B.K. Delayed treatment of spinal cord injury with erythropoietin or darbepoetin-a lack of neuroprotective efficacy in a contusion model of cord injury. Exp. Neurol. 2008, 211:34-40.
70. Bohlius J., Schmidlin K., Brillant C., Schwarzer G., Trelle S., Seidenfeld J., Zwahlen M., Clarke M.J., Weingart O., Kluge S., Piper M., Napoli M., Rades D., Steensma D., Djulbegovic B., Fey M.F., Ray-Coquard I., Moebus V., Thomas G., Untch M., Schumacher M., Egger M., Engert A. Erythropoietin or darbepoetin for patients with cancer-meta-analysis based on individual patient data. Cochrane Database Syst. Rev. 2009, 3:CD007303.
71. Hadland B.K., Longmore G.D. Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms. J. Clin. Oncol. 2009, 27:4217-4226.
72. Besarab A., Goodkin D.A., Nissenson A.R. The normal hematocrit study-follow-up. N. Engl. J. Med. 2008, 358:433-434. Normal Hematocrit Cardiac Trial Authors.
73. Wolf R.F., Peng J., Friese P., Gilmore L.S., Burstein S.A., Dale G.L. Erythropoietin administration increases production and reactivity of platelets in dogs. Thromb. Haemost. 1997, 78:1505-1509.
74. Fusté B., Serradell M., Escolar G., Cases A., Mazzara R., Castillo R., Ordinas A., Diaz-Ricart M. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb. Haemost. 2002, 88:678-685.
75. Ribatti D. Erythropoietin and cancer, a double-edged sword. Leuk. Res. 2009, 33:1-4.
76. Carlini R.G., Dusso A.S., Obialo C.I., Alvarez U.M., Rothstein M. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int. 1993, 43:1010-1014.
77. Miyashita K., Tojo A., Kimura K., Goto A., Omata M., Nishiyama K., Fujita T. Blood pressure response to erythropoietin injection in hemodialysis and predialysis patients. Hypertens. Res. 2004, 27:79-84.
78. Kharagjitsingh A.V., Korevaar J.C., Vandenbroucke J.P., Boeschoten E.W., Krediet R.T., Daha M.R., Dekker F.W. Incidence of recombinant erythropoietin (EPO) hyporesponse, EPO-associated antibodies, and pure red cell aplasia in dialysis patients. Kidney Int. 2005, 68:1215-1222.
79. Leist M., Ghezzi P., Grasso G., Bianchi R., Villa P., Fratelli M., Savino C., Bianchi M., Nielsen J., Gerwien J., Kallunki P., Larsen A.K., Helboe L., Christensen S., Pedersen L.O., Nielsen M., Torup L., Sager T., Sfacteria A., Erbayraktar S., Erbayraktar Z., Gokmen N., Yilmaz O., Cerami-Hand C., Xie Q.W., Coleman T., Cerami A., Brines M. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004, 305:239-242.
80. Erbayraktar S., Grasso G., Sfacteria A., Xie Q.W., Coleman T., Kreilgaard M., Torup L., Sager T., Erbayraktar Z., Gokmen N., Yilmaz O., Ghezzi P., Villa P., Fratelli M., Casagrande S., Leist M., Helboe L., Gerwein J., Christensen S., Geist M.A., Pedersen L.O., Cerami-Hand C., Wuerth J.P., Cerami A., Brines M. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:6741-6746.
81. Mattio M., Ceaglio N., Oggero M., Perotti N., Amadeo I., Orozco G., Forno G., Kratje R., Etcheverrigaray M. Isolation and characterization of a subset of erythropoietin glycoforms with cytoprotective but minimal erythropoietic activity. Biotechnol. Prog. 2011, [Epub ahead of print, April 20]. 10.1002/btpr.633.
82. Brines M., Grasso G., Fiordaliso F., Sfacteria A., Ghezzi P., Fratelli M., Latini R., Xie Q.W., Smart J., Su-Rick C.J., Pobre E., Diaz D., Gomez D., Hand C., Coleman T., Cerami A. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:14907-14912.
83. Kanellakis P., Pomilio G., Agrotis A., Gao X., Du X.J., Curtis D., Bobik A. Darbepoetin-mediated cardioprotection after myocardial infarction involves multiple mechanisms independent of erythropoietin receptor-common beta-chain heteroreceptor. Br. J. Pharmacol. 2010, 160:2085-2096.
84. Brines M., Patel N.S., Villa P., Brines C., Mennini T., De P.M., Erbayraktar Z., Erbayraktar S., Sepodes B., Thiemermann C., Ghezzi P., Yamin M., Hand C.C., Xie Q.W., Coleman T., Cerami A. Nonerythropoietic, tissue protective peptides derived from the tertiary structure of erythropoietin. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:10925-10930.
85. Robertson C., Cherian L., Shah M., Garcia R., Cruz-Navarro J., Grill R.J., Hand C.C., Tian T.S. Neuroprotection with an erythropoietin mimetic peptide (pHBSP) in a model of mild traumatic brain injury complicated by hemorrhagic shock. J. Neurotrauma 2011, [Epub ahead of print, May 5]. 10.1089/neu.2011.1827.
86. Ueba H., Brines M., Yamin M., Umemoto T., Ako J., Momomura S., Cerami A., Kawakami M. Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:14357-14362.